Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Deflazacort in LGMD2I
NCT03783923Phase 3Terminated
- Sponsor
- PTC Therapeutics, Inc.
- Start
- Oct 2019
- Primary completion
- Jan 2021
- Modality
- Orthosteric Ligands
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of deflazacort in limb-girdle muscular dystrophy type 2I (LGMD2I), sponsored by PTC Therapeutics, Inc. Primary endpoint: Change From Baseline in Time to Climb 4 Stairs at 26 weeks. Started Oct 2019; status: terminated.
02
Drugs
deflazacort
03
Conditions
limb-girdle muscular dystrophy type 2I (LGMD2I)
Beyond the preview
Go deeper on NCT03783923.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03783923.